Posted inBiotechnology
AI Health Coaches Get Personal: Massive Review Maps How Chatbots Could Tailor Care to You
Large language models have already rewritten the rules of how we search, write, and code. Now, according to a sweeping…
Posted inBiotechnology
Gut Microbes Hold the Key to Unlocking Soy’s Health Benefits, Review Finds
A sweeping systematic review of randomized clinical trials has delivered a sobering verdict: decades of attempts to convert people who…
Posted inBiotechnology
AI Model Flags Gastric Cancer in Patients With Psychological Symptoms
Gastric cancer remains one of the world’s most lethal malignancies, and one of its most insidious features is how quietly…
Posted inBiotechnology
Year-Long Health Innovation Training Leaves Lasting Mark on Young Doctors, Alumni Survey Finds
A year spent immersed in healthcare innovation may change how future physicians think for the rest of their careers, according…
Posted inGenetics
Advancing Brain Organoids from Research Models to Scalable Platforms
Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for…
Posted inGenetics
Microbiome Patterns Vary Among Individuals with Different Cancer Types and Onset Age
Gut microbiome. [Nopparit/Getty Images] Mayo Clinic researchers have discovered that adults aged 50 years or younger with colorectal and breast…
Posted inBiotechnology
Lilly raises diabetes weight loss bar with amylin-Zepbound combo
Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling with both obesity…
Posted inBiotechnology
Beam Therapeutics sues base editing rival, claims former scientist stole secrets
Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets…
Posted inBiotechnology
Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
Merck & Co. has touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate…
Posted inBiotechnology
GSK continues to stock up on Wave’s RNA drugs with liver-focused program
GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’…